Duchenne Muscular Dystrophy - Pipeline Review, H1 2020
Duchenne Muscular Dystrophy - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2020, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 3, 15, 8, 1, 59, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 11 and 2 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies SAS, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by AUM LifeTech Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Axolo Pharma Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by BioIncept LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Consortium.AI, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Cumberland Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by DepYmed Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by DMD Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by DTx Pharma Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Dystrogen Therapeutics SA, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Epirium Bio Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Evox Therapeutics Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by FibroGenesis LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2020
Duchenne Muscular Dystrophy - Pipeline by GlaxoSmithKline Plc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Hibernaid Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by InnoBioscience LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Ixchel Pharma LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Keros Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by LambdaGen Therapeutics, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Mitobridge Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by MyoGene Bio LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Myos Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by MyoTherix Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by NicOx SA, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Novartis AG, H1 2020
Duchenne Muscular Dystrophy - Pipeline by NS Pharma Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by OliPass Corporation, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Oncotelic Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Pepgen Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by PeptiDream Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Progenitor Therapeutics Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Prothelia Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by RASRx LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Ridgeline Therapeutics LLC, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Sarcomed AB, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Solid Biosciences Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by SOM Biotech SL, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Sutura Therapeutics Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Teijin Pharma Ltd, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Tolerion Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Pipeline by Zata Pharmaceuticals Inc, H1 2020
Duchenne Muscular Dystrophy - Dormant Projects, H1 2020
Duchenne Muscular Dystrophy - Dormant Projects, H1 2020 (Contd..1), H1 2020
Duchenne Muscular Dystrophy - Dormant Projects, H1 2020 (Contd..2), H1 2020
Duchenne Muscular Dystrophy - Dormant Projects, H1 2020 (Contd..3), H1 2020
Duchenne Muscular Dystrophy - Dormant Projects, H1 2020 (Contd..4), H1 2020
Duchenne Muscular Dystrophy - Discontinued Products, H1 2020
Duchenne Muscular Dystrophy - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned
4D Molecular Therapeutics Inc
AAVogen Inc
Akashi Therapeutics Inc
Alpha Anomeric
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
Armgo Pharma Inc
Audentes Therapeutics Inc
AUM LifeTech Inc
Avidity Biosciences LLC
Axolo Pharma Inc
Beech Tree Labs Inc
Biogen Inc
BioIncept LLC
Bioleaders Corp
Biophytis SA
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Epirium Bio Inc
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
Galapagos NV
GlaxoSmithKline Plc
Hibernaid Inc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
Keros Therapeutics Inc
LambdaGen Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MyoGene Bio LLC
Myos Inc
MyoTherix Inc
NicOx SA
Nippon Shinyaku Co Ltd
Novartis AG
NS Pharma Inc
OliPass Corporation
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
RASRx LLC
ReveraGen BioPharma Inc
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Solid Biosciences Inc
SOM Biotech SL
Sutura Therapeutics Ltd
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Vertex Pharmaceuticals Inc
Zata Pharmaceuticals Inc
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets